Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranodal Immunotherapy with Recombinant Vaccinia Virus in Melanoma
NCT00116597Phase 2Completed
- Sponsor
- University Hospital Basel
- Start
- Nov 2002
- Primary completion
- Jul 2007
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of TG6050 in melanoma, sponsored by University Hospital Basel. Started Nov 2002; status: completed.
02
Drugs
TG6050
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00116597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116597.